Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2003 2
2004 1
2005 2
2006 1
2007 7
2008 3
2009 4
2010 3
2011 3
2012 10
2013 4
2014 2
2015 2
2016 2
2017 4
2018 5
2019 4
2020 1
2021 2
2022 1
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison.
Dréno B, Bissonnette R, Gagné-Henley A, Barankin B, Lynde C, Kerrouche N, Tan J. Dréno B, et al. Am J Clin Dermatol. 2018 Apr;19(2):275-286. doi: 10.1007/s40257-018-0352-y. Am J Clin Dermatol. 2018. PMID: 29549588 Free PMC article. Clinical Trial.
BACKGROUND: Very few clinical trials have investigated the effect of topical acne treatment on scarring. OBJECTIVES: Our objective was to evaluate the efficacy of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) in atrophic acne scar formation in patien …
BACKGROUND: Very few clinical trials have investigated the effect of topical acne treatment on scarring. OBJECTIVES: Our objective was to ev …
Tolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris.
Aschoff R, Möller S, Haase R, Kuske M. Aschoff R, et al. J Drugs Dermatol. 2021 Mar 1;20(3):295-301. doi: 10.36849/JDD.2021.5641. J Drugs Dermatol. 2021. PMID: 33683070 Clinical Trial.
This evaluator-blinded pilot study compared the efficacy and tolerability of two marketed topical combination acne gels, clindamycin 1%-tretinoin 0.025% (CT) and benzoyl peroxide 2.5%-adapalene 0.1% (BA) in 20 patients with mild to moderate acne vulgaris. ...
This evaluator-blinded pilot study compared the efficacy and tolerability of two marketed topical combination acne gels, clindamycin 1%-tret …
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, Tanghetti EA. Stein Gold L, et al. Am J Clin Dermatol. 2022 Jan;23(1):93-104. doi: 10.1007/s40257-021-00650-3. Epub 2021 Oct 21. Am J Clin Dermatol. 2022. PMID: 34674160 Free PMC article. Clinical Trial.
OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne. METHODS: In a phase II, double-blind, multicente …
OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl
Adapalene/Benzoyl Peroxide Gel 0.3%/2.5%: A Safe and Effective Acne Therapy in All Skin Phototypes.
Alexis AF, Cook-Bolden FE, York JP. Alexis AF, et al. J Drugs Dermatol. 2017 Jun 1;16(6):574-581. J Drugs Dermatol. 2017. PMID: 28686775 Clinical Trial.
This analysis investigated possible differences in the efficacy and safety of the fixed dose combination of 0.3% adapalene with 2.5% benzoyl peroxide (A/BPO gel 0.3%/2.5%) in subjects with Fitzpatrick Skin Types (FST) I-VI....
This analysis investigated possible differences in the efficacy and safety of the fixed dose combination of 0.3% adapalene with 2.5% …
Adapalene/Benzoyl Peroxide Gel 0.3%/2.5%: Effective Acne Therapy Regardless of Age or Gender.
Stein Gold L, Werschler WP, Mohawk J. Stein Gold L, et al. J Drugs Dermatol. 2017 Jun 1;16(6):582-589. J Drugs Dermatol. 2017. PMID: 28686776 Clinical Trial.
Because of the many options, clinicians have a better ability to individualize treatment; however, achieving optimal results relies on understanding how various agents perform in specific population segments. Fixed-combination adapalene plus benzoyl peroxide
Because of the many options, clinicians have a better ability to individualize treatment; however, achieving optimal results relies on under …
Ceramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment.
Draelos ZD, Baalbaki N, Colon G, Dreno B. Draelos ZD, et al. J Drugs Dermatol. 2023 Jun 1;22(6):554-558. doi: 10.36849/JDD.7142. J Drugs Dermatol. 2023. PMID: 37276158 Clinical Trial.
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl peroxide (2.5%)(A/BPO), which utilizes a retinoid to normalize follicular keratinization and BPO to decrease the C. acnes population. .. …
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl
Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel.
Harper JC, Kircik LH, Gold M, Hebert AA, Sugarman JL, Green L, Gold LS, Baldwin H, Guenin E, DelRosso JQ. Harper JC, et al. J Drugs Dermatol. 2024 Mar 1;23(3):125-131. doi: 10.36849/jdd.7907. J Drugs Dermatol. 2024. PMID: 38443130 Clinical Trial.
This post hoc analysis compared threshold acne lesion reductions with clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel—the first FDA-approved triple-combination topical acne product—to its dyads and vehicle. ...
This post hoc analysis compared threshold acne lesion reductions with clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl pe
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
Eichenfield LF, Stein Gold L, Kircik LH, Werschler WP, Beer K, Draelos ZD, Tanghetti EA, Papp KA, Baldwin H, Lain E, Sadick N, Gooderham MJ, Konda A. Eichenfield LF, et al. Pediatr Dermatol. 2023 May-Jun;40(3):452-459. doi: 10.1111/pde.15283. Epub 2023 Mar 22. Pediatr Dermatol. 2023. PMID: 36949579 Clinical Trial.
BACKGROUND/OBJECTIVES: Topical clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel (IDP-126) is the first fixed-dose triple-combination formulation in development for acne. ...
BACKGROUND/OBJECTIVES: Topical clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel (IDP-126) is the fi …
Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides.
Eichenfield LF, Draelos Z, Lucky AW, Hebert AA, Sugarman J, Stein Gold L, Rudisill D, Liu H, Manna V. Eichenfield LF, et al. J Drugs Dermatol. 2013 Jun 1;12(6):611-8. J Drugs Dermatol. 2013. PMID: 23839175 Clinical Trial.
OBJECTIVE: Evaluate the efficacy and safety of adapalene 0.1%-benzoyl peroxide 2.5% gel (adapalene-BPO) in patients 9-11 years old with acne vulgaris....Adapalene-BPO was well tolerated, with mean tolerability scores less than 1 (mild)....
OBJECTIVE: Evaluate the efficacy and safety of adapalene 0.1%-benzoyl peroxide 2.5% gel (adapalene-BPO) in patie …
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants.
Baldwin H, Gold LS, Harper JC, Alexis AF, Callender VD, Kircik L, Guenin E, Eichenfield LF. Baldwin H, et al. J Drugs Dermatol. 2024 Jun 1;23(6):394-402. doi: 10.36849/JDD.8357. J Drugs Dermatol. 2024. PMID: 38834226 Clinical Trial.
BACKGROUND: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose triple-combination approved for the treatment of acne. ...
BACKGROUND: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose …
70 results